Price
Target price
€1.84
€1.84
-3.020%
-0.056
-3.020%
€3.40
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cardiol Therapeutics Inc. Stock
Cardiol Therapeutics Inc. took a tumble today and lost -€0.056 (-3.020%).
Our community is currently high on Cardiol Therapeutics Inc. with 4 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is a hugely positive potential of 63.22% for Cardiol Therapeutics Inc. compared to the current price of 1.84 €.
Our community identified positive and negative aspects for Cardiol Therapeutics Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cardiol Therapeutics Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cardiol Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
Toronto, ON – June 25, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
- Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain
- CardiolRx™ also shown to reduce inflammation in patients
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute